Pretto F et al found that RCC patients, showing over-activation of STAT3, frequently develop the cachectic syndrome, and that the STAT3 inhibitors are well worth evaluating as a therapeutic option for RCC patients [33]. The gene discussed is STAT3; the disease is renal cell carcinoma.